Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients who responded to experimental immunotherapy can now continue treatment

NCT ID NCT05572970

Disease control Sponsor: Agenus Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers balstilimab, alone or with zalifrelimab, to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who wish to stay on therapy. Only patients who completed the earlier study and meet eligibility criteria can participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
balstilimab (alone or with zalifrelimab)
What this could lead to
If successful, this expanded access program could allow patients who previously responded to these drugs to continue treatment, potentially maintaining disease control.
What could go wrong
This is an expanded access program, not a formal trial, so it does not prove safety or efficacy. Benefits seen in earlier studies may not persist, and side effects from immunotherapy (e.g., immune-related inflammation) remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    7 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Arizona Oncology Associates

    AVAILABLE

    Tucson, Arizona, 85711, United States

  • Hoag Gynecologic Oncology

    AVAILABLE

    Newport Beach, California, 92663, United States

  • Texas Oncology

    AVAILABLE

    Flower Mound, Texas, 75028, United States

  • The Ohio State University Wexner Medical Center

    AVAILABLE

    Columbus, Ohio, 43212, United States

  • University of Alabama at Birmingham

    AVAILABLE

    Birmingham, Alabama, 35249, United States

  • University of California, San Francisco Medical Center

    AVAILABLE

    San Francisco, California, 94158, United States

  • Women & Infants Hospital of Rhode Island

    AVAILABLE

    Providence, Rhode Island, 02905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.